Impact of Polymorphism on Pulmonary Pressure in Subjects With Pulmonary Hypertension of Different Cause
NCT ID: NCT00893178
Last Updated: 2021-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
350 participants
OBSERVATIONAL
2007-12-31
2021-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Especially patients with chronic heart failure can develope PH. The reasons therefore are lacking.
The researchers investigate different polymorphism and the influence of these on pulmonary artery pressure (measured invasively) in patients with congestive heart failure (CHF) and patients with primary pulmonary hypertension.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The PH measurement is due to routine catheterization, thereafter we measure different vasoactive polymorphism.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CHF with elevated PAP
CHF patients (LVEF \> 35%) with elevated mean pulmonary pressure( \> 20 mmHg ) measured by pa catheter
No interventions assigned to this group
CHF patient without elevated PAP
CHF patients (LVEF \> 35%) with normal mean pulmonary pressure
No interventions assigned to this group
Normal EF with elevated PAP
Patients with normal LVEF \< 60% with elevated mean pulmonary pressure
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients with normal LVEF and pulmonary hypertension
* right heart catheterization due to routine
* informed consent
Exclusion Criteria
* no informed consent
* elevated pulmonary pressure due to valve diseases or congenital heart disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Heart Center Leipzig - University Hospital
OTHER
University of Leipzig
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sven Möbius-Winkler
PI
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sven Möbius-Winkler, M.D
Role: PRINCIPAL_INVESTIGATOR
University Leipzig-Heart Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Heart Center Leipzig- University Leipzig
Leipzig, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SMW 03
Identifier Type: -
Identifier Source: org_study_id